Pharma stock declares ₹45 interim dividend, reports 71% net profit growth in Q3

Procter & Gamble Health said in a stock exchange filing today that “We are pleased to inform you that the Board of Directors of the Company in its meeting held today has, inter alia, approved Interim Dividend for the Financial Year 2022-23 45 per equity share (face value of Rs.10/- each). The dividend will be paid on or before March 05, 2023. As informed earlier in our letter dated January 16, 2023 Provided that the record date for the purpose of eligibility for payment of the said interim dividend shall be the 13th day of February, 2023.”

In a press release today, Procter & Gamble Health Ltd. provided its financial results for the quarter ended December 31, 2022. The company has registered a strong performance with revenue from operations. 309.97 crore in Q3FY23, as compared to Rs. 277.9 crore in Q3FY22, registering a growth of 11.54% YoY. The profit after tax (PAT) or net profit was 76.8 crore in the quarter ending December 2022 as against 44.84 crore as against that recorded in the year-ago quarter, representing a growth of 71.27% YoY. Procter & Gamble Health’s EPS Reached as compared to 45.3 in Q3FY23 27 in Q3FY22. For the six months ending December 31, 2022, sales grew by 10% to Rs. 596.6 crore from Rs. 541.0 crore in the same period last year, while the net profit for the same period increased by 40% to Rs. 140.5 crores from Rs. 100.2 crores.

Commenting on the healthy performance in Q3, Mr. Milind Thatte, Managing Director, P&G Health India said, “We sold 596.6 crore for the half year, up 10% over the year-ago period, despite macroeconomic challenges including rising inflation and higher input costs. We’ve seen continued growth in the second quarter and a promising first half of the year overall. Our encouraging financial results in the second quarter can be attributed to our core belief of bringing care closer to patients through innovative approaches. With a relentless focus on the health and well-being of patients and consumers, we launched Polybion A Injection, a new and improved formulation that enables doctors to effectively manage their patients’ recovery, while providing a good boost to energy levels. can help. On World Iron Deficiency Day, P&G Health in partnership with FOGSI (The Federation of Obstetric and Gynecological Societies of India) launches ‘Na Na Anemia Bus Yatra’, 40 across 20 cities and 5 states to create awareness on Iron One-day bus travel reduction anaemia. On World Diabetes Day 2022, as a leader in nerve health and a partner of the International Diabetes Federation, P&G Health launched a massive collective awareness effort on peripheral neuropathy, which was recognized among India’s top diabetes campaigns by Obesity International.

“Our brand and citizenship efforts in the quarter were recognized through prestigious awards – (1) CIMS Annual Wellness & Nutrition Awards ‘Trusted Brand of the Year’ (Polybion), (2) CIMS Annual Wellness & Nutrition Awards ‘Health and Wellness Product of the Year’ (Neurobion), (3) India Health & Wellness Awards ‘Gold’ for Health Awareness Campaign of the Year (Neurobion ‘Feel Life’ and Livogen ‘Letherbreakfree’) and (4) India Health & Wellness Awards’ Silver” (Sehat Public Health Initiative). This has encouraged us in our commitment to serve Indian consumers and empower them to lead healthier and more vibrant lives.”

Shares of Procter & Gamble Health Limited closed on the NSE on Friday 4,094.35 each level, up 0.15% from the previous close 4,088.40. The stock recorded a total volume of 2,928 shares as compared to 20-day average volume of 4,283 shares. Shares hit 52-week high 5,171.95 (02-Feb-2022) and hit a 52-week low 3,870.10 on (30-Dec-2022).